All In Biotech

Drug Trial Radar · NCT07623057

A Study Testing the Safety and Effects of FB102 in Healthy Volunteers

A Phase 1, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity After Single and Multiple Dose Administration of FB102 Administered Subcutaneously or Intravenously in Healthy Participants

Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

64

Planned (sponsor's estimate)

Start

Jun 23, 2026

Primary completion

Feb 2027

Study completion Jun 2027

Sponsor

Lead sponsor
Forte Biosciences, Inc.Industry
Sponsor type
Industry
First posted
Jun 3, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this Phase 1 trial is to evaluate the safety and effects of FB-102 in healthy volunteers following single and multiple doses.

Conditions

  • Healthy Volunteer

Interventions

  • FB102 Single dose - Part ABiological

    FB102 will be administered as a single dose

  • FB102 Multiple doses - Part BBiological

    FB102 will be administered once weekly for 4 doses.

  • FB102 PlaceboDrug

    Matching placebo identical to FB102 formulation but without the active pharmaceutical ingredient

  • FB102 Multiple doses - Part CBiological

    FB102 will be administered once every 2 weeks for 4 doses.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence, severity, and relationship to treatment of treatment-emergent adverse events (TEAEs)Time frame: From day 1 to Day 85 (End of treatment visit)
  2. Incidence, severity, and relationship to treatment of SAEsTime frame: From day 1 to Day 85 (End of treatment visit)

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • University of Sunshine Coast, Morayfield

    Eastwood, Queensland, Australia · Recruiting

  • University of Sunshine Coast Clinical Trials, Maroochydore

    Maroochydore, Queensland, Australia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.